Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial-Reference-Cited by-同舟云学术

Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial

Published:2018-09-11 Issue:3 Volume:185 Page:595-598
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bixby Dale¹^ORCID,Noppeney Richard²,Lin Tara L.³,Cortes Jorge⁴^ORCID,Krauter Jürgen⁵,Yee Karen⁶,Medeiros Bruno C.⁷,Krämer Alwin⁸,Assouline Sarit⁹,Fiedler Walter¹⁰,Dimier Natalie¹¹,Simmons Brian P.¹²,Riehl Todd¹²,Colburn Dawn¹²

Affiliation:

1. Division of Hematology and Medical Oncology University of Michigan Ann Arbor MI USA

2. Klinik für Hämatologie Universitätsklinikum Essen Essen Germany

3. Division of Hematologic Malignancies & Cellular Therapeutics University of Kansas Cancer Center Kansas City KS USA

4. Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston TX USA

5. Department of Haematology and Oncology Klinikum Braunschweig Braunschweig Germany

6. Department of Haematology and Oncology Princess Margaret Cancer Centre Toronto ON Canada

7. Department of Hematology Stanford University Stanford CA USA

8. Clinical Cooperation Unit Molecular Haematology/Oncology German Cancer Research Centre (DKFZ) and Department of Internal Medicine V University of Heidelberg Heidelberg Germany

9. Department of Oncology Jewish General Hospital Montreal QC Canada

10. Department of Haematology University Medical Centre Hamburg‐Eppendorf Hamburg Germany

11. Biostatistics, Roche Products Ltd Welwyn Garden City UK

12. Product Development Oncology Genentech Inc. South San Francisco CA USA

Funder

F. Hoffmann-La Roche

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15571